Organogenesis Holdings Inc. (ORGO) Earnings History
Net Loss10 years of earnings data (2016–2025) · Currently unprofitable on a TTM basis
Loading earnings history...
Organogenesis Holdings Inc. (ORGO) Earnings Overview
As of June 22, 2026, Organogenesis Holdings Inc. (ORGO) reported trailing twelve-month net income of -$284,000, reflecting +1600.0% year-over-year growth. The company earned $-0.00 per diluted share over the past four quarters, with a net profit margin of 6.6%.
Looking at the long-term picture, ORGO's 5-year EPS compound annual growth rate (CAGR) stands at +0.0%, reflecting modest earnings expansion. The company achieved its highest annual net income of $94M in fiscal 2021.
Organogenesis Holdings Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including MDXG ($31M net income, 11.6% margin), NVCR (-$173M net income, -20.8% margin), TELA (-$40M net income, -48.4% margin), ORGO has room to improve margins relative to the peer group. Compare ORGO vs MDXG →
ORGO Earnings vs Peers
Earnings metrics vs comparable public companies
ORGO Historical Earnings Data (2016–2025)
10 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $37M | +4201.0% | $56M | $0.15 | 6.6% | 9.9% |
| 2024 | $861,000 | -82.6% | -$1M | $-0.01 | 0.2% | -0.3% |
| 2023 | $5M | -68.2% | $13M | $0.04 | 1.1% | 2.9% |
| 2022 | $16M | -83.5% | $22M | $0.12 | 3.4% | 4.9% |
| 2021 | $94M | +446.6% | $72M | $0.70 | 20.2% | 15.5% |
| 2020 | $17M | +144.5% | $27M | $0.15 | 5.1% | 7.9% |
| 2019 | -$39M | +40.3% | -$30M | $-0.44 | -14.8% | -11.4% |
| 2018 | -$65M | -2996.2% | -$52M | $-0.94 | -33.5% | -26.7% |
| 2017 | -$2M | -903.3% | -$5M | $-0.03 | - | - |
| 2016 | $-208,698 | - | $208,698 | $-0.02 | - | - |
Download Data
Export ORGO earnings history in CSV or JSON format
Free sign-in required to download data
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10+ years return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ORGO — Frequently Asked Questions
Quick answers to the most common questions about buying ORGO stock.
What is ORGO earnings per share (EPS)?
ORGO trailing twelve-month (TTM) diluted EPS is $-0.00, reflecting +1600.0% year-over-year growth. The 5-year EPS CAGR is +0.0%. Complete EPS history from 2016 to 2025 is available in the table on this page.
What is Organogenesis Holdings Inc.'s net income?
Organogenesis Holdings Inc. (ORGO) trailing twelve-month net income is $-284000.00 as of 2025. Earnings grew +1600.0% year-over-year. Organogenesis Holdings Inc. has been profitable for 6 consecutive years.
Is ORGO profitable?
ORGO is not currently profitable on a TTM basis, reporting a net loss of $-284000.00. Net margin is +6.6%. Investors should monitor for a return to profitability.
What is ORGO's earnings growth rate?
ORGO compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: +7.7%, 5-Year: +0.0%, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2016 to 2025.
What are ORGO's profit margins?
Organogenesis Holdings Inc. net profit margin is +6.6%, operating margin is +9.9%, and gross margin is +75.6%. Margins are within a typical range for the sector. Return on Equity is +9.0%.
Is ORGO growing earnings?
Yes, ORGO earnings are accelerating — EPS growth of +1600.0% exceeds the 5-year CAGR of +0.0%. TTM net income reached $-284000.00. Earnings momentum is strengthening.
What was ORGO's best earnings year?
Organogenesis Holdings Inc.'s highest annual net income on record is $94M, achieved in fiscal year 2021. Earnings history on this page spans 2016 to 2025 and includes all annual and quarterly figures.
What were ORGO's earnings last quarter?
ORGO's most recent reported quarter was Q1 2026. Net income was $-56M with diluted EPS of $-0.44. For a full breakdown of all quarters, see the quarterly earnings table on this page.